| Literature DB >> 24330781 |
Elizabeth E Roughead, Lisa M Kalisch Ellett1, Emmae N Ramsay, Nicole L Pratt, John D Barratt, Vanessa T LeBlanc, Philip Ryan, Robert Peck, Graeme Killer, Andrew L Gilbert.
Abstract
BACKGROUND: The Australian Government Department of Veterans' Affairs (DVA) funds an ongoing health promotion based program to improve use of medicines and related health services, which implements interventions that include audit and feedback in the form of patient-specific feedback generated from administrative claims records. We aimed to determine changes in medicine use as a result of the program.Entities:
Mesh:
Year: 2013 PMID: 24330781 PMCID: PMC3878826 DOI: 10.1186/1472-6963-13-514
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Figure 1Components of veterans’ MATES interventions, linked to steps in the precede-proceed model.
Figure 2Intervention materials provided for the veterans’ MATES program.
Educational intervention topics and target audience
| 2: Beta-blockers, take the next step for heart failure | 6954 | 12047 | N/A | To increase beta-blocker use in veterans with heart failure | Veterans dispensed medicines indicative of heart failure who were not dispensed a heart failure specific beta blocker |
| 3: Diabetes triple check | 8573 | 16612 | 5459 | To increase use of adjunct cardiovascular medicines in veterans with diabetes | Veterans dispensed medicines indicative of diabetes (insulin and/or oral hypoglycaemics) |
| 15: Osteoporosis | 16876 | 83110 | 7967 | To increase uptake rates of bone density tests, and osteoporosis treatments | Women aged 70–79, men aged 80–85 and those over 50 years admitted to hospital with a fracture from a same level fall |
| 4: Clinical risk management: NSAIDs | 11242 | 9885 | 5447 | To reduce NSAID use in veterans with heart failure and diabetes | Veterans with dispensed medicines indicative of diabetes and/or heart failure |
| 5: Antidepressants: three steps towards safer use | 12482 | 42196 | 5447 | To reduce potentially avoidable antidepressant interactions and duplicate therapy | Veterans dispensed antidepressants |
| 6: Inhaled respiratory medicines: optimising use | 10720 | 28670 | 5447 | To decrease use of multiple devices | Veterans dispensed inhaled respiratory medicines |
| 7: PPIs in GORD: Reduce the dose – keep the benefits | 13684 | 62460 | 5447 | To encourage use of lower-strength PPIs for maintenance therapy | Veterans dispensed proton pump inhibitors |
| 8: Reducing adverse drug events for your veteran patients | 11050 | 32484 | 7074 | To reduce use of potentially inappropriate medicines in the elderly (aged over 70 years) | Veterans 70 years of age or over, dispensed medicines that should be used with caution in the elderly (according to Beers [ |
| 12: Antipsychotics in dementia | 3884 | 6690* | 8089 | To reduce antipsychotic use for behavioural and psychological symptoms of dementia (in those aged over 65 years). | Veterans aged >65 years dispensed oral antipsychotic medicines. |
| 14: COPD | 8785 | 18096 | 7880 | To reduce nebuliser use and reduce multiple device use | Veterans dispensed tiotropium or ipratropium |
| 10: Constipation: a quality of life issue for veteran patients | 9825 | 29231 | 7327 | To improve use of medicines for constipation; specifically, to increase the use of osmotic and bulk laxatives and reduce the use of contact laxatives. | Veterans dispensed laxatives |
| 13: Clopidogrel | 8279 | 16867 | 7970 | To increase use of clopidogrel with aspirin and reduce concurrent use of clopidogrel with NSAIDs | Veterans dispensed clopidogrel |
*Material was not mailed to veterans. For this topic, materials were provided to the GPs treating these 6990 patients to pass on to the patient if appropriate.
NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; GORD, gastro-oesophageal reflux disease; COPD, chronic obstructive pulmonary disease.
Impact of interventions to increase medicine use
| 2: Beta-blockers, take the next step for heart failure (n = 12047) | Increase beta-blocker use | 8.7% | Trend increasing 1.7% per month | 7% (p < 0.0001) | Trend still increasing but reduced to 0.6% per month (p < 0.0001) | 642 |
| 3: Diabetes triple check (n = 16612) | Increase ACE inhibitor use | 61.3% | Trend increasing 0.3% per month | 1.3% (p < 0.0001) | Trend still increasing but reduced to 0.1% per month (p < 0.0001) | 543 |
| Increase lipid lowering therapy use | 47.9% | Trend increasing 0.6% per month | 1.9% (p < 0.0001) | Trend still increasing but reduced to 0.5% per month (p = 0.015) | 1573 | |
| Increase antiplatelet use | 41.9% | Trend increasing 0.4% per month | 3% (p < 0.0001) | Trend still increasing but reduced to 0.1% per month (p < 0. 0.0001) | 543 | |
| 15: Osteoporosis (n = 83110) | Increase use in women | 9.1% | Trend increasing 1.1% per month | 2.8% (p < 0.004) | Trend still increasing but reduced to 0.4% per month (p < 0.0001) | 712 |
| Increase use in men | 4.7% | Trend increasing 1.5% per month | 8.3% (p < 0.0001) | Trend still increasing but reduced to 0.2% per month (p < 0.0001) | 2522 |
ACE inhibitor, angiotensin converting enzyme inhibitor.
Figure 3Example of an intervention aiming to increase medicine use.
Impact of interventions to reduce use
| 4: Clinical risk management: NSAIDs (n = 9885) | Reduce NSAID use in those with heart failure | 15.6% | Trend decreasing − 0.8% per month | −11.4% (p < 0.0001) | Trend still decreasing (non-significant to prior) − 0.7% per month (p = 0.87) | 1163 (680 heart failure patients and 483 diabetes patients) |
| Reduce NSAID use in those with diabetes | 17.9% | Trend decreasing − 1.2% per month | −10.2% (p < 0.0001) | Trend still decreasing but reduced to − 0.3% per month p = 0.006 | ||
| 5: Antidepressants: three steps towards safer use (n = 42196) | Reduce antidepressant duplication | 3.5% | Trend increasing 0.2% per month | 0.6% p = 0.72 | Trend increasing at a rate of 0.5% per month p = 0.05 | No effect |
| Reduce antidepressants with tramadol | 5.8% | Trend decreasing − 0.6% per month | −1.0% p = 0.64 | Trend still decreasing (non-significant to prior) − 0.8% per month p = 0.23 | ||
| 6: Inhaled respiratory medicines: optimising use (n = 28670) | Reduce multiple device use (3 different devices) | 9.5% | Trend increasing 0.2% per month | −0.11% p = 0.32 | Trend now decreasing (non-significant to prior) − 0.2% per month p = 0.23 | 100 patients no longer on 4 or more different devices |
| Reduce multiple device use (4 or more different devices) | 2% | Trend increasing 0.1% per month | 2% p = 0.60 | Trend now decreasing − 0.6% per month p = 0.01 | ||
| 7: PPIs in GORD: Reduce the dose – keep the benefits (n = 62460) | Reduce use of high dose proton pump inhibitors (measured as increase in low-dose use) | 2.5% | Trend of low dose increasing 0.6% per month | 14.5% (p < 0.0001) Increase in low dose use | Trend of low dose increasing at greater rate 0.9% per month (p = 0.007) | 780 |
| 8: Reducing adverse drug events for your veteran patients (n = 32484) | Reduce use of potentially inappropriate medicines | 14.7% | Trend decreasing − 0.2% per month | −0.3% p = 0.12 | Trend still decreasing (non-significant to prior) − 0.2% per month p = 0.63 | No effect |
| 12: Antipsychotics in dementia (n = 6690) | Reduce antipsychotic use | 0.54% | Trend increasing 3.6% per month | −14.3% (p < 0.0001) | Trend increasing but at a reduced rate 0.8% per month (p < 0.0001) | 1725 |
| 14: COPD (n = 18096) | Reduce multiple device use (4 or more different devices) | 2% | Trend increasing 0.1% per month | 2% p = 0.68 | Trend now decreasing − 1.1% per month p <0.0001 | 105 patients no longer on 4 or more different devices |
| Reduce use of nebules | 15.2% | Trend decreasing − 0.6% per month | 2% p = 0.07 | Trend decreasing (non-significant to prior) − 0.8% per month p = 0.2 |
NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; GORD, gastro-oesophageal reflux disease; COPD, chronic obstructive pulmonary disease.
Figure 4Example of an intervention aiming to reduce medicine use.
Interventions with combination messages (to reduce and increase medicines use)
| 10: Constipation: a quality of life issue for veteran patients (n = 29231) | Increase use of osmotic laxatives | 1.5% | Trend increasing 0.7% per month | 1.8% (p = 0.11) | Trend increasing at greater rate 1.2% per month (p = 0.002) | 2047 (825 additional people on osmotic laxatives, 410 additional people on contact laxatives and 690 less people on bulk laxatives) |
| Decrease use of contact laxatives | 2.5% | Trend increasing 0.2% per month | 3.0% (p = 0.0007) | Trend still increasing (non-significant to prior) 0.2% per month (p = 0.87) | ||
| Increase use of bulk laxatives | 1.9% | Trend decreasing − 0.7% per month | 0.8% (p = 0.34) | Trend now decreasing at greater rate − 0.9% per month (p = 0.04) | ||
| 13: Clopidogrel (n = 16867) | Increase use of clopidogrel with aspirin | 1.5% | Trend increasing 0.8% per month | 3.0% (p = 0.018) | Trend still increasing (non-significant to prior) 0.7% per month (p = 0.4) | 1114 (825 now on aspirin with clopidogrel, 289 no longer on NSAIDs with clopidogrel) |
| Reduce concurrent use of clopidogrel with NSAIDs | 1% | Trend decreasing − 0.3% per month | −5.3% (p = 0.002) | Trend still increasing (non-significant to prior) 0.1% per month (p = 0.3) |
Stakeholder evaluation: stakeholders who found the information “useful or very useful” (GPs and pharmacists) or “helpful or very helpful” (veterans)
| 2: Beta-blockers, take the next step for heart failure | 69% | N/A* | 81% |
| 3: Diabetes triple check | 71% | 92% | 82% |
| 4: Clinical risk management: NSAIDs | 73% | 95% | 80% |
| 5: Antidepressants: three steps towards safer use | 81% | 92% | 81% |
| 6: Inhaled respiratory medicines: optimising use | 80% | 91% | 86% |
| 7: PPIs in GORD: Reduce the dose – keep the benefits | 81% | 95% | 72% |
| 8: Reducing adverse drug events for your veteran patients | 84% | 95% | 86% |
| 10: Constipation: a quality of life issue for veteran patients | 84% | 92% | 72% |
| 12: Antipsychotics in dementia | 85% | 93% | N/A* |
| 13: Clopidogrel | 86% | 98% | 87% |
| 14: COPD | 79% | 90% | 77% |
| 15: Osteoporosis | 84% | 92% | 77% |
| Average | 80% | 93% | 80% |
#Percent of GPs, veterans or pharmacists who provided feedback.
*No feedback was sought from pharmacists for intervention 2 or from veterans for intervention 12.